title: Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
authors.forename: D
authors.initials: D
authors.lastname: Guillén
authors.forename: I
authors.initials: I
authors.lastname: Bobolea
authors.forename: O
authors.initials: O
authors.lastname: Calderon
authors.forename: A
authors.initials: A
authors.lastname: Fiandor
authors.lastname: Cabañas R
authors.forename: R
authors.initials: R
authors.lastname: Heredia
authors.forename: S
authors.initials: S
authors.lastname: Quirce
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects* / Q000276:immunology; D055963:Asthma, Aspirin-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D008875:Middle Aged; D000069444:Omalizumab; D013997:Time Factors; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D018926:Anti-Allergic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D001241:Aspirin